GlassScriptPhysician profile
Parvesh Kumar
NPI 1497805378
$2,986.42
in general payments reported to CMS, 2019-2025
10 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2022: $671 · 2023: $341 · 2024: $79.00 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $1,376 · Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $1,376.00 |
| Food and Beverage | $729.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Telix Pharmaceuticals | $1,653.51 | 2025 | Illuccix |
| Siemens Medical Solutions USA, INC. | $447.20 | 2022-2023 | |
| Foundation Medicine, INC. | $364.78 | 2022-2023 | Foundationone Cdx |
| Sirtex Medical INC | $188.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $111.69 | 2024-2025 | |
| Pfizer INC. | $99.82 | 2023 | |
| Medtronic, INC. | $46.89 | 2023 | Micra |
| Reflexion Medical, INC. | $39.84 | 2023 | Reflexion Medical Radiotherapy System |
| Varian Medical Systems, INC. | $20.22 | 2019 | |
| Janssen Scientific Affairs, LLC | $13.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvesh Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.